Abstract
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström’s Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have